New pen injector for hemophilia drug tested in healthy men
NCT ID NCT05681845
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a new pen injector delivers the drug Mim8 into the blood as well as a standard syringe and cartridge. 205 healthy men received a single injection of Mim8 using either the pen or the syringe. The goal was to see if the pen works just as well, making it easier for people with hemophilia A to take their medicine. Participants were not treated for hemophilia A, as they were healthy volunteers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, 10117, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an ultra-long-acting factor VIII simplify surgery for hemophilia a patients?
- Patient voices take center stage in haemophilia a treatment decisions
- Japanese study tracks Esperoct's Real-World safety over two years
- Japanese hemophilia patients monitored on alhemo in new safety study
- New hope for haemophilia a patients: immune tolerance induction may eliminate clotting factor blockers
- New hope for kids with hemophilia: can SCT800 stop bleeds before they start?